# The Effect of Acetaminophen on Oxidative Modification of Low-Density Lipoproteins in Hypercholesterolemic Rabbits

Meral Baş Özsoy and Aysun Pabuçcuoğlu\*

Department of Biochemistry, Faculty of Pharmacy, Ege University, Bornova 35100, Izmir, Turkey

Received 7 September, 2006; Accepted 1 December, 2006

Summary Oxidative modification of low-density lipoproteins (LDL) contributes to the pathology of atherosclerosis. Antioxidants may protect LDL against oxidative modification. Acetaminophen, a widely used analgesic and antipyretic agent, has significant antioxidant properties. However, there is little evidence to suggest that acetaminophen acts as an antioxidant for LDL oxidation in vivo. In this study, we investigated the in vivo effect of acetaminophen on LDL oxidation in hypercholesterolemic rabbits. The oxidative modification of LDL was identified by conjugated dienes and thiobarbituric acid-reactive substances (TBARS). In the cholesterol group which rabbits were fed a diet contained 1% g cholesterol for 8 weeks, TBARS contents and conjugated diene levels in the plasma and isolated LDL samples significantly increased compared with the control rabbits (p < 0.05). However, in the cholesterol + acetaminophen group, the TBARS contents and conjugated diene levels were significantly lower than that of the cholesterol group (p < 0.05). The results from *in vitro* studies also demonstrated that the LDL isolated from serum was oxidized by Cu<sup>++</sup> ions and this oxidation reduced in the presence of acetaminophen. The reduced oxidative modification of LDL by acetaminophen may be of therapeutic value in preventing the development and progression of atherosclerosis.

## Key Words: Oxidation of LDL, atherosclerosis, acetaminophen, hypercholesterolemia, rabbit

# Introduction

Atherosclerosis and related cardiovascular diseases remain a major health problem in developed countries. High plasma total cholesterol and low density lipoproteins (LDL) levels show significant positive correlation to the development of atherosclerosis and cardiovascular diseases [1, 2]. It was reported that the cholesterol content of erythrocytes, platelets, polymorphonuclear leukocytes and endothelial cells increased in hypercholesterolemia and this increase activate these cells and cause the enhanced production of oxygen free radicals [3, 4].

LDL, the major carrier of blood cholesterol, is thought to become atherogenic after undergoing oxidative modifications. It was known that LDL oxidation is accompanied by alteration in its biological properties, such as endothelial cell damage, uptake via scavenger receptors in macrophages, formation of foam cells and fatty streak and increased amounts of mediators of cell proliferation and platelet aggregation [1, 2, 5–8].

Many studies have been focused on mechanisms of LDL oxidation. It was shown that *in vitro* LDL oxidation can be induced by transition metal ions, hypochlorite, superoxide/ nitric oxide, organic peroxyl radicals, tocopheryl radicals and peroxidases, the *in vivo* mechanisms for LDL oxidative modification has not yet identified [1, 2, 5–10].

A number of drugs with antioxidant capacity have been

<sup>\*</sup>To whom correspondence should be addressed. Tel: +90 232 3880110 ext:3984 Fax: +90 232 3885258 E-mail: aysun.pabuccuoglu@ege.edu.tr

shown to protect LDL against oxidative modification [11-13]. Such drugs may have beneficial therapeutic values in the prevention of atherosclerosis. Acetaminophen, widely used analgesic and antipyretic drug, is an example which possesses significant antioxidant effects under certain experimental conditions [14-17]. However, literature survey has indicated the paradoxical results for the effect of acetaminophen on LDL oxidation. Some in vitro studies demonstrated that oxidative modification of LDL with Cu2+-ions, azo compounds and peripheral blood mononuclear cells are significantly reduced by acetaminophen [16, 18], others contrarily claimed that acetaminophen may also act as a catalyst of LDL oxidation by myeloperoxidase [19]. Moreover, unique in vivo data available for the effects of acetaminophen on LDL oxidation in the literature is an abstract reporting limited experimental details [20].

Those conflicting results encourage us to investigate the *in vivo* effect of acetaminophen on LDL oxidation in hypercholesterolemic rabbits in order to clarify the paradox.

# **Materials and Methods**

## Reagents and chemicals

Trisodium citrate anhydrous, 2-thiobarbituric acid, 1,1,3,3tetramethoxy propane and bovine serum albumin (BSA) were obtained from Sigma (St. Louis, MO). Heparin was obtained from Liquemine 25000 IU/ml, Roche. Paracetamol (4-hydroxyacetanilide, 4-acetamidophenol) was obtained from Fluka. Cholesterol (95%) was obtained from ABCR Gmb. & Co. Cholesterol, high-density lipoprotein (HDL)-cholesterol and triglyceride enzymatic kits were from Randox Laboratories Ltd., Antrim, UK. Agarose gels (Titan gel lipoprotein electrophoresis system) were purchased from Helena Laboratories, Beaumont, TX USA. Other chemicals used were of analytical grade.

## Animals and diets

Male New Zealand white rabbits weighed from 1.4 to  $2 \text{ kg} \text{ (mean} \pm \text{SD} = 1.6 \pm 0.16 \text{)}$  were studied. They were housed in individual cages in a room maintained at a constant temperature and kept on a 12:12 h light-dark cycle. After a 1-month period of adaptation of the animals, the experiment was started. Food and water were given daily and any unused food discarded. The control group (n = 10)was fed with the standard rabbit diet (Flaran, Izmir, Turkey). The cholesterol group (n = 10) was fed with standard rabbit diet containing 1% cholesterol (w/w). The acetaminophen group (n = 10) were fed with the standard diet containing 1% cholesterol and treated with acetaminophen 200 mg/day for 8 weeks. The acetaminophen dose (200 mg/daily) is reported to relevant for analgesic effect to rabbits by oral route [21]. Acetaminophen solution in water was prepared daily and was administered to rabbits by gavage.

All animal protocols were approved by the Ege University, Faculty of Pharmacy Animal Care and Use Committee.

## Blood sample collection

For biochemical determinations, blood was taken from the central ear vein and collected in the test tubes containing ethylenediaminetetraacetic acid (EDTA) as anticoagulant at the beginning and at the end of the 8-weeks period. Plasma was recovered by centrifugation at 4°C, 1500 g for 15 min. At the end of the study period, 10 ml venous blood from an ear vein of each animal was drawn into a tube to obtain serum for LDL isolation.

## Preparation of LDL

LDL was isolated by buffered heparin as described in the literatures [22, 23]. The precipitation buffer consisted of 0.064 M trisodium citrate adjusted to pH 5.05 with 5N HCI, and contained 50.000 IU/l heparin. Before precipitation of LDL, serum samples (to which 1 mg/ml of EDTA were added) and precipitation reagents were allowed to equilibrate to room temperature. 1 ml of the sample was added to 7 ml of the heparin-citrate buffer. After mixing with a vortex, the suspension was allowed to stand for 10 min at room temperature. The insoluble lipoproteins were then sedimented by centrifugation at 1000 g for 10 min. The pellet was resuspended in 1 ml of 0.1 M Na-phosphate buffer, pH 7.4, containing 0.9% of NaCI. The concentration of LDL protein was measured by the Lowry method using bovine serum albumin as standard [24].

#### $Cu^{++}$ -mediated oxidation of LDL

The isolated LDL from normal human serum was incubated with 10  $\mu$ M CuSO<sub>4x</sub> 5H<sub>2</sub>O for 6 and 24 hours in 37°C in the absence and presence of acetaminophen. The oxidation of LDL was identified by measurement of thiobarbituric acid reactive substances (TBARS) content and agarose gel electrophoresis.

#### Plasma lipids analysis

Plasma total cholesterol (TC), triglyceride (TG) and HDL-cholesterol were determined enzymatically using a commercial kit (Randox Lab. Ltd. Crumin, UK). LDL-cholesterol was calculated by Friedewald formula [25].

# Identity of oxidized LDL

Oxidation of LDL was identified by measuring two parameters: the formation of conjugated dienes, the production of TBARS.

TBARS content was used to represent lipid peroxide levels and measured by spectrophotometric assay using 1,1,3,3-tetramethoxy propane as a standard, as described by Yagi and Satoh [26, 27]. The results were expressed as nmoles of malondial dehyde equivalents.

The conjugated dienes in LDL lipids were determined directly by measuring the absorbance at 234 nm [22, 28]. Lipids were extracted from LDL samples by chloroformmethanol (2:1), dried under nitrogen, then redissolved in cyclohexane, and analyzed spectrophotometrically at 234 nm. Absorbance units were converted to molar units using the molar extinction coefficient  $2.95 \times 10^4$  M<sup>-1</sup> cm<sup>-1</sup>. The results were expressed as µmol/l to have an estimation of actual level of oxidized LDL in circulation.

#### Statistical analysis

All determinations were carried out in duplicate and median values  $\pm$  SD were calculated. Differences between groups were assessed by Kruskal-Wallis and Mann-Witney non-parametric statistical tests. A difference was considered significant when p<0.05.

# Results

Table 1 shows the plasma levels of TC, TG, HDLcholesterol, LDL-cholesterol and TBARS at the beginning (0 week) and at the end of the experiment (8 weeks). At the beginning of the experiment, plasma lipid levels of three groups were similar. However, feeding a cholesterol diet to rabbits for 8 weeks significantly increased the plasma TC, LDL-cholesterol and TG levels, in comparison to controls (p<0.05).

No significant differences in rabbit weights were observed at the end of the study  $[2.49 \pm 0.14 \ (0 \text{ week}) - 2.48 \pm 0.12 \ (8 \text{ weeks}), 2.498 \pm 0.08 - 2.451 \pm 0.086, 2.5 \pm 0.08 - 2.42 \pm 0.11 \text{ kg for control, cholesterol and cholesterol + acetaminophen groups, respectively].}$ 

As shown in Table 1, the plasma TBARS levels in the cholesterol group were significantly higher than that of the controls (p<0.05). However, in the cholesterol + acetaminophen group, the plasma TBARS levels were significantly lower than that of the cholesterol group (p<0.05).

Table 2 shows TBARS contents and conjugated diene levels in isolated LDL samples from experimental groups serum. The result indicated that TBARS and conjugated diene levels in isolated LDL from the cholesterol group were significantly higher than that of the control group (p<0.05). However, TBARS and conjugated diene levels in cholesterol + acetaminophen group has lowered when compared to the cholesterol group levels (Table 2) (p<0.05).

The results from *in vitro* studies demonstrated that the LDL samples isolated from normal human serum was oxidized by  $Cu^{++}$  ions and this oxidation reduced in the presence of acetaminophen (Table 3).

Table 1. The effect of high cholesterol diet on plasma lipid levels and TBARS content in rabbits

Experimental period (week)	Experimental group	Total cholesterol (mg/dl)	Triglyceride (mg/dl)	HDL-cholesterol (mg/dl)	LDL-cholesterol (mg/dl)	TBARS (nmol/ml)
0	Control	$39.73\pm9.27$	$77.85 \pm 23.98$	$13.71\pm2.75$	$8.85 \pm 4.02$	$0.701\pm0.05$
	Cholesterol	$42.71\pm7.14$	$143.28\pm30.96$	$16.26\pm6.52$	$10.75\pm3.05$	$0.720\pm0.05$
	Cholesterol + Acetaminophen	$44.60\pm8.99$	$74.24\pm29.60$	$14.13\pm1.60$	$7.90 \pm 1.25$	$0.740\pm0.07$
8	Control	$28.98 \pm 14.25$	$60.35\pm19.03$	$7.56 \pm 2.57$	$7.36\pm5.10$	$0.725\pm0.05$
	Cholesterol	$745.89 \pm 280.36 *$	$182.35 \pm 101.14$	$9.73 \pm 2.54$	$588.28 \pm 219.88 *$	$0.923\pm0.16\text{*}$
	Cholesterol + Acetaminophen	534.73 ± 264.25*	$57.75 \pm 18.82$	$8.16\pm3.60$	$510.25 \pm 253.47*$	$0.717 \pm 0.05 **$

The results are expressed as means  $\pm$  SD of ten animals per group.

\*p<0.05, significant difference to the control group.

\*\*p<0.05, significant difference to the cholesterol group.

Table 2.	Conjugated	diene	levels	and	TBARS	content	in	LDL	isolated	from
rabbits ser	um									

Experimental groups	TBARS (nmol/mg LDL protein)	Conjugated diene levels (µM/mg LDL protein)
Control	$0.07\pm0.02$	$6.40 \pm 1.33$
Cholesterol	$0.15\pm0.06^{\rm a}$	$17.26\pm6.63^{\rm a}$
Cholesterol + Acetaminophen	$0.10\pm0.04^{\text{a,b}}$	$11.61 \pm 2.22^{a,b}$

The results are expressed as Means  $\pm$  SD of ten animals per group.

<sup>a</sup> p<0.05, significant difference to the control group.

<sup>b</sup> p<0.05, significant difference to the cholesterol group.

	TBARS levels (nmol/mg protein) (Mean $\pm$ SD) ( $n = 5$ )		
	Incubation time		
	6 hours	24 hours	
Control (LDL + PBS)	$2.12\pm0.19$	$2.27\pm0.23$	
LDL + Cu <sup>++</sup> (Oxidized LDL)	$7.54\pm0.83^{\rm a}$	$7.78\pm0.45^{\rm a}$	
$LDL + Cu^{++} + A (0.1 \text{ mM})$	$5.64\pm0.30^{\text{a,b}}$	$5.79\pm0.34^{\rm a,b}$	
$LDL + Cu^{++} + A (0.5 \text{ mM})$	$5.43\pm0.28^{\text{a,b}}$	$5.38\pm0.33^{\text{a,b}}$	
$LDL + Cu^{++} + A (1 mM)$	$5.09\pm0.17^{\rm a,b}$	$5.09\pm0.15^{\text{a,b}}$	
$LDL + Cu^{++} + A (2 mM)$	$3.62\pm0.25^{\text{a,b}}$	$3.88\pm0.74^{\text{a,b}}$	

Table 3. TBARS levels of LDL samples after incubation of Cu<sup>++</sup> ions for 6 and 24 hours

A: Acetaminophen

<sup>a</sup> p<0.05 significant difference to control LDL.

<sup>b</sup> p<0.05 significant difference to oxidized LDL.

#### Discussion

There is a contradiction about the effect of acetaminophen on LDL oxidation as prooxidant or antioxidant. It has been shown that acetaminophen is a potent inhibitor for Cu<sup>++</sup>-induced and cell-mediated LDL oxidation *in vitro* [16]. In addition, Chou *et al.* [18] demonstrated that myeloperoxidase(MPO)-H<sub>2</sub>O<sub>2</sub>-nitrite mediated oxidation of LDL was inhibited by acetaminophen. However, Kapiotis *et al.* [19] found that acetaminophen increased LDL oxidation by MPO that generate phenoxyl radical and act as a catalyst of LDL oxidation in MPO-induced reaction systems. These conflicting results may be attributed to the different experimental conditions employed in the studies.

On the other hand, Merrill *et al.* [14, 15] have reported that acetaminophen causes an important cardioprotective effect on isolated heart tissue from experimental animals. Similarly, Taylor *et al.* [20] have examined the effect of acetaminophen on the formation of atherosclerotic plaques in the cholesterol fed rabbit model and this study was published as abstract without detailed experimental data. They reported that formation of atherosclerotic plaques was significantly decreased at the end of the study and acetaminophen has capable to inhibit the formation of oxysterols in LDL.

Those conflicted results encourage us to investigate the *in vivo* effect of acetaminophen on LDL oxidation in hyper-cholesterolemic rabbits.

Table 1 indicates that the cholesterol-supplemented diet caused marked alterations in the plasma lipoproteins, particularly an increase of LDL and a decrease of HDL in comparison with the control group. These findings indicated that hypercholesterolemia was occurred.

The most widely used methods for monitoring LDL oxidation are the measurement of conjugated dienes and

TBARS levels [30-33]. Beside the plasma TBARS levels, conjugated diene levels and TBARS contents in the isolated LDL samples from the cholesterol group were also significantly higher than that of the control group (p<0.05) (Table 2). It is known that high cholesterol diet induce production of oxygen free radicals leading to lipid peroxidation. The significant increase of plasma lipid peroxidation in cholesterol-fed rabbits agrees with previous reports [32, 33].

The addition of acetaminophen to daily diet (200 mg/kg a day) was clearly reduced TBARS and conjugated diene levels when compared to the cholesterol group levels (see the cholesterol + acetaminophen group in Table 2). The reductive effect of acetaminophen on LDL oxidation may well be related with its antioxidant capacity which is attributed to its phenolic structure and are believed to work out via scavenging free radicals [*16*, *17*, *34*, *35*].

As a result, our study demonstrate that; (1) after 8 weeks of feeding 1% g cholesterol diet, rabbits developed significant elevations of plasma lipid levels; (2) cholesterol-enriched diet increased in lipid peroxidation; (3) the administration of 200 mg/daily acetaminophen to cholesterol feeding rabbits reduced lipid peroxidation. On the otherhand, the results from *in vitro* studies demonstrated that the LDL samples isolated from serum was oxidized by Cu<sup>++</sup> ions and this oxidation reduced in the presence of acetaminophen (Table 3).

At this point, a suggestion can be made that acetaminophen might have a therapeutic value as an alternative drug for prevention of atherosclerosis which is one of the main causes of human death in industrialized countries.

# Acknowledgments

This study was supported by grants from the TUBITAK (101S254) and Ege University Research Foundation (2001EC22003).

## References

- Heinecke, J.W.: Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. *Atherosclerosis*, **141**, 1–15, 1998.
- [2] Heinecke, J.W.: Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. *Curr. Opin. Lipidol.*, 8, 268–274, 1997.
- [3] Prasad, K. and Kalra, J.: Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am. *Heart J.*, **125**, 958–973, 1993.
- [4] Ohara, J., Peterson, T.E., and Harrison, D.G.: Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest., 91, 2546–2551, 1993.
- [5] Salvayre, R., Auge, N., Benoist, H., and Negre-Salvayne, A.: Oxidized low density lipoprotein-induced apoptosis. *Biochim. Biophys. Acta.*, **1585**, 213–221, 2002.
- [6] Steinberg, D.: Low density lipoprotein oxidation and its

pathobiological significance. J. Biol. Chem., 272, 20963-20966, 1997.

- [7] Heinecke, J.W.: Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. *Free Radic. Biol. Med.*, **32**, 1090–1101, 2002.
- [8] Itabe, H.: Searching for oxidized low-density lipoproteins in vivo. J. Clin. Biochem. Nutr., 37, 1–8, 2005.
- [9] Berliner, J.A. and Heinecke, J.W.: The role of oxidized lipoproteins in atherogenesis. *Free Radic. Biol. Med.*, 20, 707–727, 1996.
- [10] Wagner, P. and Heinecke, J.W.: Copper ions promote peroxidation of low density lipoprotein lipid by binding to histidine residues of apolipoprotein B100, but they are reduced at other sites on LDL. *Arterioscler. Thromb. Vasc. Biol.*, **17**, 3338–3346, 1997.
- [11] Yasuhara, M., Suzumura, K., Tanaka, K., Takahashi, M., Aoki, S., Odawara, A., Narita, H., and Suzuki, T.: Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. *Biol. Pharm Bull.*, 23, 570–574, 2000.
- [12] Rosenson, R.S.: Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. *Atherosclerosis*, **173**, 1– 12, 2004.
- [13] Pentikainaen, M.O., Lindstedt, K.A., and Kovanen, P.T.: Inhibition of the oxidative modification of LDL by nitecapone. *Arterioscler. Thromb. Vasc. Biol.*, **15**, 740–747, 1995.
- [14] Merrill, G., McConnell, P., Vandyke, K., and Powell, S.: Coronary and myocardial effects of acetaminophen: protection during ischemia-reperfusion. *Am. J. Physiol. Heart Circ. Physiol.*, **280**, H2631–H2638, 2001.
- [15] Merrill, G.F. and Goldberg, E.: Antioxidant properties of acetaminophen and cardioprotection. *Basic Res. Cardiol.*, 96, 423–430, 2001.
- [16] Nenseter, M.S., Halvorsen, B., Rosvold, O., Rustan, A.C., and Drevon, C.A.: Paracetamol inhibits copper ion-induced, azo compound-initiated, and mononuclear cell-mediated oxidative modification of LDL. *Arteioscler. Thromb. Vasc. Biol.*, **15**, 1338–1344, 1995.
- [17] Dinis, T.C.P., Madeira, V.M.C., and Almeida, L.M.: Action of phenolic derivatives (acetaminophen, salicylate, and 5aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. *Arch. Biochem. Biophys.*, 315, 161–169, 1994.
- [18] Chou, T. and Greenspan, P.: Effect of acetaminophen on the myeloperoxidase-hydrogen peroxide-nitrite mediated oxidation of LDL. *Biochim. Biophys. Acta.*, **1581**, 57–63, 2002.
- [19] Kapiotis, S., Sengoelge, G., Hermann, M., Held, I., Seelos, C., and Gmeiner, B.M.K.: Paracetamol catalyzes myeloperoxidaseinitiated lipit peroxidation in LDL. *Arteioscler: Thromb. Vasc. Biol.*, **17**, 2855–2860, 1997.

- [20] Taylor, A.A., Raya, J., Rogers, L.K., and Smith, C.V.: Acetaminophen inhibits fatty streak formation and LDL oxysterols in hipercholesterolemic rabbits (abstract). *Circulation*, **100**, Suppl: S697, 1999.
- [21] Flecknell, P.: Assessment and alleviation of post-operative pain. *Newsletter*, 8, 8–14, 1997/1998.
- [22] Ahotupa, M., Ruutu, M., and Mantyla, E.: Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. *Clin. Biochem.*, 29, 139–144, 1996.
- [23] Ahotupa, M., Marniemi, J., Lehtimaki, T., Talvinen, K., Raitakari, O.T., Vasankari, T., Viikari, J., Luoma, J., and Yla-Herttuala, S.: Baseline diene conjugation in LDL lipits as a direct measure of *in vivo* LDL oxidation. *Clin. Biochem.*, **31**, 257–261, 1998.
- [24] Wieland, H. and Seidel, D.: A simple specific method for precipitation of low density lipoproteins. J. Lipid Res., 24, 904–909, 1983.
- [25] Lowry, O., Rosebrough, N.J., Farr, A.L., and Randall, R.J.: Protein measurement with the folin phenol reagent. *J. Biol. Chem.*, **193**, 265–275, 1951.
- [26] Rifai, N., Warnick, R., McNamara, J.R., Belcher, J.D., Grinstead, G.F., and Frantz, I.D.: Measurement of low density lipoprotein cholesterol in serum: status report. *Clin. Chem.*, 38, 150–160, 1992.
- [27] Yagi, K.: Assay for blood plasma or serum. *Methods Enzymol.*, 105, 328–331, 1984.
- [28] Satoh, E.: Serum lipit peroxide in cerebrovascular disorders determined by a new colorimetric method. *Clin. Chim. Acta.*, 90, 37–43, 1978.
- [29] Buege, J.A. and Aust, S.D.: Microsomal lipid peroxidation. *Methods Enzymol.*, **52**, 302–310, 1978.
- [30] Abuja, P.M. and Albertini, R.: Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. *Clin. Chim. Acta.*, **306**, 1–17, 2001.
- [31] Puhl, H., Waeg, G., and Esterbauer, H.: Methods to determine oxidation of low-density lipoproteins. *Methods Enzymol.*, 233, 425–441, 1994.
- [32] Liu, B.W., Jiang, Y., Fu, M.D., Liu, Y., and Fan, P.: Oxidative modification of lipoproteins in hypertriglyceridemic patients and hypercholesterolemic rabbits *in vivo*. *Mol. Cell Biochem.*, 207, 131–135, 2000.
- [33] Mahfouz, M.M. and Kummerow, F.A.: Cholesterol-rich diets have different effects on lipit peroxidation, cholesterol oxides, and antioxidant enzymes in rat and rabbits. *J. Nutr. Biochem.*, **11**, 293–302, 2000.
- [34] Chong, P.H., Kezele, B., and Pontikes, P.J.: Effect of acetaminophen on atherosclerosis. *Annal. Pharmacother.*, 35, 1476–1479, 2001.
- [35] Osakabe, N.: Cacao polyphenols and atherosclerosis. J. Clin. Biochem. Nutr., 37, 67–72, 2005.